Submitted by Anonymous (not verified) on 2 October 2025 - 15:22
Human medicines European public assessment report (EPAR): Elahere, mirvetuximab soravtansine, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Elahere, mirvetuximab soravtansine, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised